Viromed Medical AG Advances with Unique Lung Treatment

Viromed Medical AG announced the progress of its cold plasma therapy for severe lung infections, highlighting a globally unique preclinical database. Presented by Prof. Dr. Hortense Slevogt, the study uses Viromed's Cold Atmospheric Plasma (CAP) technology aimed at treating severe infectious lung diseases.

Over 2.5 years of research on human lung epithelial models showed promising pathogen reduction with no significant tissue damage. This provides an internationally unique foundation for non-pharmacological treatments. The current validation study at Saarland University is crucial for confirming dosing parameters under realistic conditions.

The therapeutic focus is on ventilator-associated pneumonia, with potential preventive applications against viral and bacterial infections. Facing rising antibiotic resistance and high pneumonia mortality, Viromed sees its CAP technology as meeting a significant international need in intensive care.